Breakthrough pain is a transitory flare of pain superimposed on an otherwise stable pain pattern in patients treated with opioids. 1 Breakthrough pain is a common feature in patients with cancer and is associated with significant physical, psychologic and economic burdens on patients as well as their care-givers. 2 The most common subtype of breakthrough pain is incident pain, which is due to movement and is commonly associated with bone metastases or fractures. 2 Breakthrough pain can also be idiopathic and occur spontaneously, with no obvious precipitating event. Another type of breakthrough pain is the incident non-predictive pain that is precipitated by non-volitional factors (e.g.
If pain is not adequately reduced, in the absence of treatment-limiting side-effects an increase in the ATC opioid dose may be considered in an effort to reduce the frequency or intensity of breakthrough pain.
Examples of potent opioid agonists used for managing background pain include:
• transdermal fentanyl;
• controlled-release oxycodone;
• extended-release hydromorphone;
• methadone, morphine (controlled-, sustained-and extended-release formulations); and
• extended-release oxymorphone.
These drugs are characterized by a slow onset of action and their pharmacokinetic profiles have minimal peaks and troughs that result in stable blood levels over the dose period. 7 Studies have shown that increasing the ATC opioid medication may result in improved background and breakthrough pain. 8, 9 Even though these studies are on a small scale, optimization of ATC opioid dose is a potential strategy for managing breakthrough pain, with the opioid dose being lowered again if the patient experiences adverse effects between episodes of breakthrough pain. 10 
Adjuvant Analgesics
In addition to these steps, the use of adjuvant drugs can be considered at all stages of the patient's illness and at each step of the WHO analgesic ladder. 11 Adjuvant analgesics are a diverse group of drugs that were originally developed for a primary indication other than pain. Many of these medications are currently used to enhance analgesia under specific circumstances. Of interest, a few of these agents are currently used as primary analgesics for specific pain conditions as well as adjuvants in some other pain conditions. 12 Adjuvant analgesics (e.g.
antidepressants, anticonvulsants, N-methyl-D-aspartic acid antagonists, corticosteroids, and topicals) can be administered alone, but they are usually accompanied by acetaminophen/NSAIDS and opioids. 11 Adjuvant analgesics are widely used, especially for the relief of neuropathic cancer pain, which can present with a component of breakthrough pain.
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Supplemental Analgesia
The use of supplemental doses of analgesics is the cornerstone of pharmacologic treatment strategies for managing breakthrough pain.
This type of medication is taken as required, rather than on a regular basis. The ideal supplementary analgesic should be efficacious, with a rapid onset, relatively short duration of action, and minimal adverse effects. It can be used either prophylactically, for predictable volitional incident pains or procedural pains, or at the onset of breakthrough pain for unpredictable spontaneous pain or non-volitional incident pains. Non-opioid analgesics and adjuvant analgesics have been used/ investigated as supplemental medication for episodes of breakthrough pain, but they typically have a slow onset and relatively long duration of action. [15] [16] [17] For this reason, in the majority of cases the most appropriate supplemental medication will be an opioid analgesic.
The most common method of providing supplemental medication is with oral short-acting formulations of morphine and other opioid analgesics. 
Parenteral Opioids
The parenteral routes of opioid administration (intravenous and subcutaneous) have been shown to be effective, well tolerated, and safe for the management of breakthrough pain. 18, 19 The use of parenteral opioids is, however, associated with several disadvantages. For example, any indwelling intravenous catheter can become a site of infection and thus requires skilled nursing attention if the patient is unable to care for catheter access. 20 In addition to this, more costs are involved as this route requires preparation of the opioid solution for injection by the pharmacist and administration of the infusion via an external pump. 20 Despite this, the rapid onset of action associated with this route of administration means that it may be acceptable in cases where the breakthrough pain is severe. 21 
Oral Transmucosal Opioids
The oral transmucosal routes of administration (buccal and sublingual)
have increasingly been used in the management of breakthrough pain episodes. 22 The mouth provides a large mucosal surface for drug absorption, allowing drugs to enter the systemic circulation directly, bypassing the gastrointestinal tract and first-pass metabolism in the liver. has demonstrated a faster onset of relief and greater degree of breakthrough pain relief than oral morphine. 24, 25 In addition, a Cochrane review confirmed the effectiveness of this modality for treating breakthrough pain and reported that OTFC produced faster/greater analgesia than oral morphine.
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A second oral transmucosal product with marketing authorization in the US and Europe is the effervescent buccal fentanyl tablet. 26 This tablet provides rapid penetration of fentanyl through the buccal mucosa by using effervescence to cause pH shifts that enhance the rate and extent of fentanyl absorption. The efficacy of this formulation has been shown in placebo-controlled studies that demonstrated an analgesia onset that was faster than would be expected from oral therapy. [27] [28] [29] [30] available. Fentanyl buccal soluble film (FBSF) is a transmucosal delivery system based on a polymer film. It delivers fentanyl across the mucosa in a pH-dependent manner. 31 FBSF was shown to be efficacious and safe in a placebo-controlled study of breakthrough pain patients 32 and has recently been approved in this setting in the US, Canada, and Europe.
A sublingual tablet formulation of fentanyl that uses mucoadhesives to hold the fentanyl in contact with the mucosa has also been marketed in Europe and has recently received Food and Drug Administration (FDA) approval in the US. Sublingual fentanyl citrate comes as a rapidly disintegrating tablet consisting of an ordered mixture of fentanyl combined with soluble carrier particles that is rapidly absorbed. 33 This formulation was tested in a randomized, placebo-controlled phase III trial in opioid-tolerant patients with breakthrough cancer pain. Here, sublingual fentanyl citrate provided significant improvements in pain intensity compared with placebo from 10 minutes post-administration. It was well-tolerated both systemically and sublingually. 34 
Intranasal Opioids
The intranasal route is another option for achieving rapid uptake of opioids. It is currently being used/investigated to provide acute and breakthrough pain relief. The large absorptive surface area of the nasal mucosa is highly vascular and thus offers rapid absorption of drugs into the systemic circulation while bypassing gastrointestinal and hepatic pre-systemic metabolism. 35 This route of administration may be more acceptable to patients who experience nausea, vomiting, oral mucositis, impaired gastrointestinal function, and xerostomia, for whom the oral route of administration may be difficult.
A potential disadvantage with the intranasal route is the relatively small volume of drug the nose is able to accommodate. The efficacy of intranasal fentanyl spray (INFS) was compared with that of OTFC for the relief of cancer-related breakthrough pain in an open-label trial. 36 The difference in pain intensity was significantly greater for the INFS than OFTC from five minutes post-dosing. Clinically important pain relief (≥33% reduction in pain intensity) was seen five minutes after INFS treatment in a quarter of breakthrough pain episodes.
A second intranasal fentanyl formulation, fentanyl pectin nasal spray provided rapid analgesia and clinically meaningful pain relief (≥2 point decrease in pain intensity on a 0-10 numerical scale) versus placebo in a randomized, double-blind study in breakthrough cancer pain patients.
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IFNS and fentanyl pectin nasal spray were well-tolerated and patient acceptability of the intranasal formulations was high in both studies. 36, 37 Both INFS and OTFC are approved in Europe for the management of breakthrough pain. Other fentanyl formulations and devices for intranasal administration are currently being developed. These include an intranasal formulation of the fentanyl analog sufentanil, which was shown to be safe and effective in a prospective, open-label study of patients with cancer-related breakthrough pain. 38 
Inhaled Opioids
The lungs present a large surface area for drug absorption but there are limited data investigating the use of inhaled opioids in patients with breakthrough pain. This may be because the route has a number of limitations. It requires complex devices to create a mist prior to inhalation, as well as various types of nebulizers (depending on the patient). 39 
Rectal Opioids
Rectal administration of opioids offers the possible pharmacokinetic advantage of directly entering the systemic circulation via the lower rectal veins. It is also useful for patients who are unable to tolerate oral or parenteral routes due to bleeding disorders or generalized edema. 40 Several types of rectal opioid preparations may be formulated, depending on the country and the acceptance of patients and care
givers. In the US, compounding pharmacies can prepare opioid (e.g. hydromorphone) suppositories. The administered dose is usually the same as the oral dose.
Even though rectal administration can provide rapid pain relief, absorption rates are variable, and therefore the amount of pain relief can also vary for the doses administered. 41 In a study of 100 patients with chronic cancer-related pain, patients were asked to complete a questionnaire concerning the acceptability of nine administration routes.
The rectal route was the least acceptable. 21 The decision to use a specific opioid preparation should be based on a combination of:
• the pain characteristics (onset and duration);
• the product characteristics (pharmacokinetics and pharmacodynamics);
• the patient's previous response to opioids (efficacy and tolerability); and particularly
• the patient's preference for an individual preparation.
Dosing of Supplemental Opioid Analgesia
Traditionally, based largely on anecdotal experience, is has been advised that a supplemental opioid dose roughly equivalent to 5-10% of the total opioid background medication dose should be administered as needed every two to four hours. 1 The European Association for Palliative Care (EAPC) guidelines on morphine use in cancer pain recommend the use of the equivalent of a four-hourly dose (approximately 16% of the daily dose) of usual opioid to control breakthrough cancer pain. 22, 42 Studies investigating various supplemental opioid formulations have, however, suggested the absence of a relationship between the effective dose of these preparations and the fixed ATC opioid dose. 24, 27, 28, 30, 37 The current recommendation is therefore that each patient is titrated to a successful dose of supplemental opioid that produces adequate analgesia and minimal adverse effects. 43 The need to titrate transmucosal opioid doses is the subject of much debate. For example, OTFC given in doses proportional to the basal opioid regimen has been found to be quite effective and, above all, safe in treating breakthrough pain. 22, 44 Further clinical studies are necessary to examine this issue.
prescribing a drug for breakthrough pain, the 'Four As' of pain treatment should be considered: 46 • analgesia;
• activities of daily living;
• adverse events; and
• aberrant drug-taking behaviors.
In addition, a task group of the UK and Ireland Association for Palliative
Medicine made a series of 12 recommendations about certain generic strategies to manage breakthrough pain (see Table 1 ). 47 A key point emphasized by this group was that the successful management of breakthrough pain depends on adequate reassessment of the patient, the objective of which is to determine the efficacy and tolerability of the treatment and any change in the nature of the breakthrough pain.
Inadequate reassessment may lead to the continuance of ineffective and/or inappropriate treatment. 47 In the absence of a validated clinical breakthrough pain assessment tool, the group recommended the use of standard pain scales to determine the response to treatment (e.g. verbal and numerical rating scales), the choice of which should be made on an individual basis.
Current Status and Future Challenges
Although the effective treatment of background and breakthrough cancer pain is a major goal for physicians involved with pain management, the possible aberrant use of opioids is a concern. There is a fear of drug misuse or abuse in:
• vulnerable patients with positive risk factors or a past history of addiction; and
• in the subpopulation of patients affected by both drug addiction and cancer pain, especially when immediate-release and rapid-onset opioid formulations are used.
Therefore, many chronic pain patients can be left undertreated, resulting in unrelieved pain and diminished quality of life. 48 It is known that patients with a history of drug abuse and psychiatric illness are more likely to abuse opioid medication. 49 The opioid risk tool and the screener and opioid assessment for patients with pain are examples of tools in the form of brief, self-administered written surveys. These can predict the level of risk for developing aberrant drug-related opioid use behaviors in patients. 50, 51 It has been suggested that all patients that are treated with opioids should be monitored in order to identify and manage opioid abuse.
Moreover, higher-risk patients should be watched more closely and have monitored prescriptions so that appropriate pain relief is provided while aberrant drug-related behavior is prevented.
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A practical approach recommended for monitoring opioid use involves having the patient agree that opioids will be prescribed by a single provider and supplied by a single pharmacy. 53 An additional suggestion is that a limited drug supply be offered to the patient, with limited refill opportunities (e.g. in the case of theft). Higher risk patients should be required to make more frequent visits for prescriptions and other important monitoring tools can be scheduled, such as random urine toxicology screening and pill counts. Later in the same year, the FDA approved the first opioid with an associated REMS program: FBSF. As part of the FBSF REMS, this dosage form will only be available through a restricted distribution program called the FOCUS program. 56 The development of REMS for extended-release opioid products is still the subject of much discussion and consultation between the FDA, industry, and other stakeholder groups.
Conclusion
Breakthrough pain is a heterogeneous condition and its management may involve a number of different interventions, including opioids, which have traditionally played an important role in breakthrough pain management. In some cases, optimizing ATC opioids may be helpful;
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